A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions

Advanced Malignant Tumors

Interventions

DRUG

IAP0971

IAP0971 should be subcutaneous injected，q3w

Trial Locations (1)

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

SUNHO（China）BioPharmaceutical CO., Ltd.

INDUSTRY